Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyGarenoxacin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Garenoxacin
- Accession Number
- DB06160
- Type
- Small Molecule
- Groups
- Investigational
- Description
Garenoxacin (INN) is a quinolone antibiotic undergoing regulatory review for the treatment of gram-positive and gram-negative bacterial infections. [Wikipedia]
- Structure
Structure for Garenoxacin (DB06160)
- Synonyms
- desquinolone
- External IDs
- T-3811
- Product Ingredients
Ingredient UNII CAS InChI Key Garenoxacin Mesylate OXI6EF55FR 223652-90-2 IGTHEWGRXUAFKF-NVJADKKVSA-N - Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antineoplastic Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Fluoroquinolones
- Moderate Risk QTc-Prolonging Agents
- QTc Prolonging Agents
- Quinolines
- Quinolones
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- UNII
- V72H9867WB
- CAS number
- 194804-75-6
- Weight
- Average: 426.42
Monoisotopic: 426.139113458 - Chemical Formula
- C23H20F2N2O4
- InChI Key
- NJDRXTDGYFKORP-LLVKDONJSA-N
- InChI
- InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
- IUPAC Name
- 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- SMILES
- C[C@H]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O
Pharmacology
- Indication
Investigated for use/treatment in bacterial infection.
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (4R)-limonene (4R)-limonene may increase the neuroexcitatory activities of Garenoxacin. 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Garenoxacin. 19-norandrostenedione The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin. 5-androstenedione The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Garenoxacin. Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Garenoxacin. Aceclofenac Aceclofenac may increase the neuroexcitatory activities of Garenoxacin. Acemetacin Acemetacin may increase the neuroexcitatory activities of Garenoxacin. Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Garenoxacin. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Garenoxacin. Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Garenoxacin. - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- ChemSpider
- 110579
- ChEBI
- 131716
- ChEMBL
- CHEMBL215303
- Wikipedia
- Garenoxacin
- ATC Codes
- J01MA19 — Garenoxacin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0232 mg/mL ALOGPS logP 1.71 ALOGPS logP 1.62 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 6.05 ChemAxon pKa (Strongest Basic) 8.88 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 78.87 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 110.37 m3·mol-1 ChemAxon Polarizability 42.39 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Isoindolines / Isoindoles / Aralkylamines / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Amino acids show 10 more
- Substituents
- Quinoline-3-carboxylic acid / Dihydroquinolone / Dihydroquinoline / Isoindoline / Isoindole / Isoindole or derivatives / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aralkylamine / Benzenoid show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Inhibitor
- Curator comments
- This drug is a fluoroquinolone, and these agents are known to inhibit CYP1A2.
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Rodighiero V: Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999 Nov;37(5):399-431. [PubMed:10589374]
- Bril F, Gonzalez CD, Di Girolamo G: Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf. 2010 Jan;5(1):85-92. [PubMed:20210724]
- Zhang L, Wei MJ, Zhao CY, Qi HM: Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008 Dec;29(12):1507-14. doi: 10.1111/j.1745-7254.2008.00908.x. [PubMed:19026171]
Drug created on March 19, 2008 10:14 / Updated on October 01, 2018 16:46